Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Interactive:
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Quiz
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Exams
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions

Infectious Diseases


Answer 8
  1. Pegylated interferon. EMC, also called type II cryoglobulinemia, is often induced by HCV infection. For a progressive systemic disease such as EMC, active therapy with pegylated interferon is indicated. Plasmapheresis is a therapeutic option in patients with acute severe disease. Therapy for hepatitis C, including combination therapy with pegylated interferon and ribavirin, has been shown to be beneficial in patients with EMC; however, patients may experience disease recurrence following completion of therapy. Ribavirin is contraindicated in the setting of renal insufficiency, but it has been used successfully in low doses in patients with mild to moderate renal insufficiency.6

    REFERENCE
    6. Kalia H, Lopez PM, Martin P. Treatment of HCV in patients with renal failure. Arch Med Res 2007;(6):628-33.

Click here to return to the questions

 

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 11/6/07 • kkj